Nemolizumab Delivers Long-term Relief for Children Aged 2-11 With AD
Nemolizumab showed long-term symptom relief in children aged 2 to 11 with moderate-to-severe atopic dermatitis, per data presented at PeDRA 2026.
Topic
Il 31
Topic
Il 31
IL-31 Targets Hair Follicle Bulge and Delays Anagen Entry in Mice
A Journal of Investigative Dermatology study finds IL-31 signals at the hair follicle bulge across species and slows plucking-ind…
Zai Lab to Detail First ZL-1503 Trial Data in Atopic Disease Program
Zai Lab's announced first-in-human readout for ZL-1503, an IL-13/IL-31Rα bispecific antibody in atopic diseases, offers no endpoi…
Nemolizumab holds three-year atopic dermatitis response curve
NEMLUVIO (nemolizumab) sustained atopic dermatitis responses across three years in a long-term extension cohort, per PharmaTimes.…
Nemolizumab Sustains Atopic Dermatitis Control Through 3 Years
Long-term data show nemolizumab maintained skin clearance and itch control in atopic dermatitis patients through 3 years of conti…
Nemluvio Shows Three-Year Durability in Atopic Dermatitis
Galderma presented three-year Nemluvio® data at Fall Clinical 2026 showing deep, lasting lesion and itch responses in atopic derm…
Nemolizumab Sustains Atopic Dermatitis Response at 3 Years
Three-year extension data show nemolizumab sustains response in adults with moderate-to-severe atopic dermatitis, according to co…
Galderma Presents New Nemluvio Data in Atopic Dermatitis Aged 12+
Galderma has presented new Nemluvio (nemolizumab) data showing responses in patients with atopic dermatitis aged 12 and older, ad…